Results 41 to 50 of about 140,561 (343)
The Egyptian Journal of Internal Medicine, 2019 Background Transarterial chemoembolization (TACE), a locoregional therapy, is widely recommended as first-line treatment for intermediate-stage hepatocellular carcinoma (HCC).
Ahmed A Ghafar +4 more
doaj +1 more source
First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI) [PDF]
, 2012 The objective of this pilot clinical study was to assess the safety, technical feasibility, pharmacokinetic (PK) profile and tumour response of DC Bead™ with irinotecan (DEBIRI™) delivered by intra-arterial embolisation for the treatment of metastatic ...
Eichler, Katrin +6 more
core +1 more source
Obesity as a cause of hepatocellular carcinoma
Annals of Hepatology, 2015 During recent years the incidence of obesity has increased significantly, and in some instances rapidly, in many resource-rich countries. Paralleling this increase has been an increase in the incidence of hepatocellular carcinoma.
Michael C. Kew
doaj +1 more source
Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards [PDF]
, 2019 PURPOSE:To report clinical effectiveness, toxicity profile, and prognostic factors of combined 100 μm ± 25 and 200 μm ± 50 epirubicin-loaded polyethylene glycol (PEG) microsphere drug-eluting embolic transcatheter arterial chemoembolization protocol in ...
Argirò, Renato +12 more
core +1 more source
Gastroenterology Research and Practice, 2009 Background. Transjugular liver biopsy (TJLB) is frequently used to obtain liver specimens in high-risk patients. However, TJLB sample size possibly limits their clinical relevance. Methods. 102 patients that underwent TJLB were included.
Max G. Beckmann +9 more
doaj +1 more source
Transplantation Direct, 2020 Background. A United Network for Organ Sharing policy change in 2015 created a 6-mo delay in the receipt of T2 hepatocellular carcinoma exception points.
Claire Durkin, MD +2 more
doaj +1 more source
Tubeimoside-2 Triggers Methuosis in Hepatocarcinoma Cells through the MKK4–p38α Axis
Pharmaceutics, 2023 Liver cancer, consisting mainly of hepatocellular carcinoma, is the third leading cause of cancer-related mortality worldwide. Despite advances in targeted therapies, these approaches remain insufficient in meeting the pressing clinical demands. Here, we
Yichao Gan +9 more
doaj +1 more source
Midzonal Necrosis as a Pattern of Hepatocellular Injury After Shock
Gastroenterology, 1984 Midzonal necrosis is rarely observed in human liver, except in patients with yellow fever. In a retrospective analysis of livers from 1000 consecutively autopsied adult patients, we observed midzonal necrosis in 1.8% of the cases, and in 8% of patients with centrilobular necrosis.
S M, de la Monte +3 more
openaire +2 more sources
Expression of a Secretory Protein C1qTNF6, a C1qTNF Family Member, in Hepatocellular Carcinoma
Analytical Cellular Pathology, 2011 Background: Recent studies have revealed that the adiponectin-associated protein belonging to the C1qTNF family mediates various biological processes. However, the pathobiological property of C1qTNF6 in carcinogenesis remains unclear.
Tamotsu Takeuchi +2 more
doaj +1 more source
Au-24 as a potential thioredoxin reductase inhibitor in hepatocellular carcinoma cells
Pharmacological Research, 2022 A novel TrxR inhibitor Au-24 and its inhibitory ability to hepatocellular carcinoma in vitro and in vivo is reported herein. Au-24 can suppress HepG2 cells from proliferating by lowering mitochondrial membrane potential (MMP) and increasing reactive ...
Gaopan Dong +7 more
doaj +1 more source